LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-24. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Defenders said that in addition to its modest efficiency, belimumab allowed patients to significantly reduce their use of corticosteroids. Belimumab was not effective in Phase II clinical trials for rheumatoid arthritis. It was moderately effective in Phase II trials for Sjögren syndrome. In December 2020, belimumab was approved by the FDA as a treatment for lupus nephritis in combination with standard treatment.
=== Regional === Rabbi Eliyahu Zini, the uncle of Shin Bet Chief David Zini, criticized the agreement with the Lebanese government, asserting, "all of Lebanon belongs to us." He questioned Israeli ministers, asking, "Are you normal? You are giving up the inheritance of our ancestors on what basis?". Hezbollah expressed conditional acceptance of the ceasefire, warning that Israeli military presence in Lebanon would justify continued resistance. Lebanese political figures advised civilians to delay returning to affected areas until the terms and stability of the agreement became clearer.
== Academic career == After Edlich completed his 8-year residency training at the University of Minnesota Hospital, he completed a 2-year plastic surgical residency at the University of Virginia Health Sciences Center. During his time at the University of Virginia School of Medicine, both in his residency and subsequent career, he published hundreds of publications and book chapters on burn care, wound healing, surgical instrument design, and rehabilitation. He began his research career at the University of Virginia Health Sciences Center and was involved in the development of the burn unit and prehospital care service.
Any purchase using a reusable cup was to award three entries. On March 7, 2020, due to the COVID-19 pandemic, Tim Hortons announced that it had cancelled the distribution of physical cups for the promotion due to concerns that the virus could be spread by returned cups, and that the promotion would be conducted solely via the app. The chain had also joined others in temporarily prohibiting the use of reusable cups for similar reasons. The changes from 2020 remained in use through 2024, with the promotion therefore being renamed to "Roll Up to Win". In addition, Tim Hortons announced that every electronic entry would be guaranteed to win Tims Rewards points at a minimum. In February 2025, Tim Hortons announced that physical cups would return to the promotion alongside digital entries for a limited time.
Sources: en.wikipedia.org
=== Latest history === In April 2022, the business announced it would acquire Sierra Oncology Inc. for $1.9 billion ($55 per share). In May 2022, GSK announced it would acquire Affinivax and its phase II 24-valent pneumococcal vaccine candidate for up to $3.3 billion, strengthening its vaccine business. On 16 May 2022, the company changed its name from GlaxoSmithKline to GSK. In April 2023, GSK announced it would acquire Bellus Health Inc. for $2 billion. In February 2024, the company acquired Aiolos Bio for over $1 billion, adding to its existing asthma business through AIO-001, a long-acting monoclonal antibody that targets the thymic stromal lymphopoietin cytokine. In May 2024, GSK sold off its 4.2% shareholding in Haleon for $1.58 billion. In July 2024, GSK moved its headquarters from Brentford to New Oxford Street in central London. As of 2025, capital investments in the company via its American Depository Receipts in New York were outpacing those via the company's primary listing in London. Mounting speculation that GSK would be moving its primary share listing to the New York Stock Exchange, following similar speculation about rival AstraZeneca, has been met with denials from GSK's corporate executives. In September 2025, the company announced Emma Walmsley was stepping down as chief executive at the beginning of 2026. GSK has appointed Luke Miels as her replacement, who has been the company's chief commercial officer since 2017.
=== Single-particle measurements === Generally speaking single-particle measurement instruments desorb particles one at a time using a pulsed laser. The process is called laser desorption/ionization (LDI) and is the primary ionization method used for single-particle measurements. The main advantage of using LDI over thermal desorption, is the ability to analyze both non-refractory and refractory (e.g., mineral dust, soot) components of atmospheric aerosols. Laser vaporization allows precise laser firing when individual particles fly through the vaporization zone, and the systems are thus dubbed single particle mass spectrometers (SPMS). Several versions of SPMS have been reported, including the aerosol time-of-flight mass spectrometer (AToFMS), the laser mass analyzer for particles in the airborne state (LAMPAS), particle analysis by laser mass spectrometer (PALMS), the rapid single-particle mass spectrometer (RSMS), the bioaerosol mass spectrometer (BAMS) b194 Steele et al., 2003), the nanoaerosol mass spectrometer (NAMS), the single-particle laser ablation time-of-flight mass spectrometer (SPLAT), the single-particle aerosol mass spectrometer (SPAMS), and laser ablation aerosol particle time-of-flight mass spectrometer (LAAP-ToF-MS). Among the most commons of these instruments is the aerosol time-of-flight mass spectrometer (AToFMS).
Alniditan acts as a selective serotonin 5-HT1B and 5-HT1D receptor full agonist. To a much lesser extent, it is also a full agonist of the serotonin 5-HT1A receptor and an agonist of the serotonin 5-HT2B receptor. Conversely, alniditan is essentially inactive at the serotonin 5-HT1E, 5-HT1F, and 5-HT2A receptors. The broad receptor interactions of alniditan have been studied and reported.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.